These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 38244064)
1. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose. Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064 [TBL] [Abstract][Full Text] [Related]
2. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN; J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study. Cerqueira-Silva T; Shah SA; Robertson C; Sanchez M; Katikireddi SV; de Araujo Oliveira V; Paixão ES; Rudan I; Junior JB; Penna GO; Pearce N; Werneck GL; Barreto ML; Boaventura VS; Sheikh A; Barral-Netto M PLoS Med; 2023 Jan; 20(1):e1004156. PubMed ID: 36630477 [TBL] [Abstract][Full Text] [Related]
5. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study. Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H Front Immunol; 2024; 15():1448408. PubMed ID: 39606247 [TBL] [Abstract][Full Text] [Related]
6. Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses. Padilla-Bórquez DL; Matuz-Flores MG; Hernández-Bello J; Rosas-Rodríguez JA; Turrubiates-Hernández FJ; García-Arellano S; González-Estevez G; Ceja-Galvez HR; Oregon-Romero E; López-Reyes A; Muñoz-Valle JF Hum Vaccin Immunother; 2024 Dec; 20(1):2394265. PubMed ID: 39246041 [TBL] [Abstract][Full Text] [Related]
7. Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations. Serwanga J; Ankunda V; Katende JS; Baine C; Oluka GK; Odoch G; Nantambi H; Mugaba S; Namuyanja A; Ssali I; Ejou P; Kato L; ; Musenero M; Kaleebu P Front Immunol; 2024; 15():1348905. PubMed ID: 38357547 [TBL] [Abstract][Full Text] [Related]
8. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698 [TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from Niu M; Mu Y; Adriko M; Candia R; Jones MK; McManus DP; Egwang TG; Cai P Front Public Health; 2024; 12():1437063. PubMed ID: 39624416 [TBL] [Abstract][Full Text] [Related]
10. Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients. Mendizabal M; Ducasa N; Benencio P; Anders M; Cairo F; Barbero M; Etcheves P; Alter A; Scarton G; Abraldes JG; Biglione M; Mauro E Hepatol Commun; 2022 Oct; 6(10):2850-2859. PubMed ID: 35903818 [TBL] [Abstract][Full Text] [Related]
11. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010. Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R; Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389 [TBL] [Abstract][Full Text] [Related]
13. No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial. Naficy A; Kuxhausen A; Seifert H; Hastie A; Leav B; Miller J; Anteyi K; Mwakingwe-Omari A Hum Vaccin Immunother; 2024 Dec; 20(1):2327736. PubMed ID: 38513689 [TBL] [Abstract][Full Text] [Related]
15. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study. Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653 [TBL] [Abstract][Full Text] [Related]
16. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines. Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168 [TBL] [Abstract][Full Text] [Related]
17. Self-Reported COVID-19 Vaccine and Booster Acceptance and Hesitancy Among Autistic Adults in Pennsylvania: Cross-Sectional Analysis of Survey Data. Shea L; Cooper D; Ventimiglia J; Frisbie S; Carlton C; Song W; Salzer M; Lee B; Hotez E; Vanness DJ JMIR Public Health Surveill; 2024 Aug; 10():e51054. PubMed ID: 39196609 [TBL] [Abstract][Full Text] [Related]
18. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. Martin CA; Nazareth J; Jarkhi A; Pan D; Das M; Logan N; Scott S; Bryant L; Abeywickrama N; Adeoye O; Ahmed A; Asif A; Bandi S; George N; Gohar M; Gray LJ; Kaszuba R; Mangwani J; Martin M; Moorthy A; Renals V; Teece L; Vail D; Khunti K; Moss P; Tattersall A; Hallis B; Otter AD; Rowe C; Willett BJ; Haldar P; Cooper A; Pareek M EClinicalMedicine; 2023 Apr; 58():101926. PubMed ID: 37034357 [TBL] [Abstract][Full Text] [Related]
19. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study. Hviid A; Nieminen TA; Pihlström N; Gunnes N; Dahl J; Karlstad Ø; Gulseth HL; Sundström A; Husby A; Hansen JV; Ljung R; Hovi P Eur Heart J; 2024 Apr; 45(15):1327-1335. PubMed ID: 38365960 [TBL] [Abstract][Full Text] [Related]